Intellia Therapeutics Inc. (NTLA)
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Intellia Therapeutics is pioneering in-vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster status. Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships, like with Regeneron, make it a compelling buy opportunity. The company's innovative use of lipid nanoparticles for gene delivery and a robust pipeline position it as a leader in the CRISPR space, targeting large markets.
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Q2 2024 Earnings Call Transcript
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations & Corporate Communications John Leonard - President & Chief Executive Officer Laura Sepp-Lorenzino - Executive Vice President & Chief Scientific Officer Ed Dulac - Executive Vice President & Chief Financial Officer Conference Call Participants Mary Kate Davis - Bank of America Dae Gon Ha - Stifel Joseph Thome - TD Cowen Luca Issi - RBC Gena Wang - Barclays Maury Raycroft - Jefferies Mani Foroohar - Leerink Rick Bienkowski - Cantor Fitzgerald Jay Olson - Oppenheimer Timor Vanicus - Raymond James Silvan Tuerkcan - Citizens JMP William Pickering - Bernstein Myles Minter - William Blair David Lebowitz - Citi Operator Good morning, and welcome to Intellia Therapeutics' Second Quarter 2024 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago.
The 3 Best Cathie Wood Stocks to Buy in August 2024
As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks.
Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
The future is here
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Bull Case for Intellia Therapeutics Stock Just Got Even Stronger
Intellia Therapeutics makes gene editing therapies. Some of those therapies could theoretically cure certain patients.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Let's get down to it: why should investors consider pharma stocks? Primarily, it comes down to the permanence of the underlying narrative.
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
Intellia Therapeutics has a gene editing therapy that looks to be quite effective. That's favorable for the program's chances of getting approved.
